Q32 Bio

Q32 Bio AAQS

The The AAQS of Q32 Bio (QTTB) as of Oct 16, 2026 is 1. In the previous year, The AAQS was 1.00 — a change of 0.00% (lower).

AAQS

1

YoY

0.00%

Last updated:

Q32 Bio has a current AAQS of 1.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Q32 Bio in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Q32 Bio AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2017
1.00 USD
Jan 1, 2018
1.00 USD
Jan 1, 2019
1.00 USD
Jan 1, 2020
1.00 USD
Jan 1, 2021
1.00 USD
Jan 1, 2022
1.00 USD
Jan 1, 2023
1.00 USD
Jan 1, 2024
1.00 USD
The Q32 Bio AAQS history
YEARAAQSYoY
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
1—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Q32 Bio Stock analysis

What does Q32 Bio do? Q32 Bio Inc, trading under the ticker QTTB with ISIN US7469641051, is a biotechnology company based in Bedford, United States. The company operates within the Health Care sector, specifically in the Biotechnology industry. Q32 Bio Inc has 24 employees and completed its initial public offering (IPO) on March 28, 2018. The company's website is https://www.homologymedicines.com/. While the source description provided references Homology Medicines, Inc. and includes details such as a 205-employee count, an IPO date of March 28, 2018, and a lead product candidate named HMI-102 for phenylketonuria (PKU), these details are inconsistent with the provided company profile. The factual information for Q32 Bio Inc includes its location, sector, employee count, IPO date, and website. The company is engaged in developing treatments for rare diseases at the genetic level, focusing on monogenic diseases affecting various tissues including the liver, central nervous system, bone marrow, lung, and eye. The company utilizes a platform of adeno-associated virus vectors for gene editing and therapy approaches. However, specific details about product names, additional employee figures, or other operational specifics beyond the provided data are not included in the factual profile. Q32 Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Q32 Bio stock

The AAQS of Q32 Bio is 1 in 2024.

On Eulerpool you can find the complete historical development of The AAQS Q32 Bio since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Q32 Bio

All Key Metrics — Q32 Bio